Pharmaceuticals co., KaloBios, announces search for $40M
KaloBios, a Palo Alto company developing treatments for pseudomonas lung infections and autoimmune diseases including rheumatoid arthritis, is looking to raise up to $40 million in a third round of funding.
Newly-appointed KaloBios chief executive David Pritchard told VentureWire about his plans (sub required).
Next Story: Cisco employee Victor Tsao on investment binge, backs Tzero
Previous Story: Sequoia backs Google competitor Guruji, in India
